Erasca is a San Diego based precision oncology company that rebuilt itself around a single in licensed RAS franchise. The company now runs two clinical programs, ERAS zero one five a pan RAS molecular glue and ERAS four zero one a pan KRAS inhibitor, both with FDA cleared INDs. The spring 2026 Phase 1 data for ERAS zero one five are the core of the investment case. In second line KRAS G12X non small cell lung cancer the monotherapy objective response rate reached 62% at the pharmacologically active doses. That figure trailed no approved standard of care in the same setting by a wide margin. The later 2026 update extended the durability evidence and confirmed that the safety profile held up with longer follow up.
The balance sheet tells a second story. Erasca raised $242.7 million in a January offering at $10.00 per share. It then raised $593.5 million in a July offering at $17.50 per share, a steep repricing of the equity in a single fiscal quarter. Cash and marketable securities stood at $384.3 million at the June 30 balance sheet date. The market now prices the stock near $16.19 with a market capitalization close to $5.7 billion. The debate is whether that multiple is justified by the depth of the lung cancer data or is front running a pivotal program that has not yet started.
The forward path runs through a potential registration enabling trial in second line lung cancer and a Phase 3 first line pancreatic trial, each expected to start within the next twelve months. The central question is whether the company can convert a Phase 1 response rate into a confirmable survival benefit in a population where the existing targeted options are already moving the needle. That is a question that carries real weight for a company with no approved products.